Contineum Therapeutics (CTNM) Interest Coverage Ratio (2023)
Contineum Therapeutics (CTNM) recorded quarterly Interest Coverage Ratio of 335.66 in Q2 2023, up 703.74% quarter-over-quarter from 55.6 in Q1 2023.
Contineum Therapeutics (CTNM) Interest Coverage Ratio (2023) Analysis & Trends
Contineum Therapeutics' Interest Coverage Ratio history runs 1 years deep, the most recent figure standing at 335.66 for Q2 2023.
- In Q2 2023, Interest Coverage Ratio changed N/A year-over-year to 335.66; the TTM figure through Mar 2024 stood at 0.61 (changed N/A YoY), while the FY2023 annual figure was 23.49, changed N/A from the prior year.
- Interest Coverage Ratio was 335.66 for Q2 2023 at Contineum Therapeutics, up from 55.6 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 335.66 in Q2 2023 to a low of 55.6 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3.58 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -258.33 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 11.50 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 11.79 |
| 10 | Contineum Therapeutics | 423.05 Mn | 423.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 335.66 |
| Mar 31, 2023 | -55.60 |